NVST

EnvistaD

NYSE / Health Care Equipment & Services

At close

2026-06-02

Current thesis

Execution on product rollouts and an uptick in procedure volumes could push Envista toward the high end of sell-side targets; successful margin expansion or meaningful share gains in consumables would support upside to or above the analyst high.

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta +0.0.

What can break

Adverse FX moves or rising raw-material costs compressing margins

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $24.54 · Bull $30.00 · Bear $14.22

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-01 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

As of 2026-02-09 • Model: RankAlpha Sentiment AI

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $28.46

Why

Momentum21 · Δ7d -3.0

Value62 · Δ7d +0.0

Sentiment46 · Δ7d +3.3

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

34% active weight

Current posture

7d trendSoftening

Δ7d

-3.0

Δ21d

-40.5

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.0

Δ21d

+0.8

Sentiment

33% active weight

Current posture

7d trendImproving

Δ7d

+3.3

Δ21d

+11.2

Why this grade

Composite grade D. Momentum 20.8 / Value 62.4 / Sentiment 45.6

Fundamentals (TTM)

As of 2026-06-01

Market Cap

$3.8B

Beta

1.01

Shares Out

164.43M

P/E (TTM)

269.7

P/S (TTM)

1.41

P/FCF (TTM)

14.13

Rev YoY

+11.5%

EPS YoY

-484.6%

Gross Margin

+55.6%

Op Margin

+7.2%

Net Debt

$325.2M

Current Ratio

2.37

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology